ARCHIVES

Charges Against CC Probed; Most Found Invalid

This article is from The Cancer Letter archive.

Vol. 04 No. 13 | March 31, 1978

Download PDF Visit The Full Archive

Related Articles

Two Phase III Ramucirumab Trials Both Deliver Improved Overall and Progression-Free Survival

October 25, 2013

Tracor Could Earn $186,000 As Prime Contractor On Carcinogenesis Bioassay

April 26, 1974

NIH to Hold Meeting On Faculty Design

February 2, 1996

Dingell Asks FDA To Explain Failure To Curtail ESA Ads.

June 15, 2007

Bevacizumab Improves PFS In Advanced Kidney Cancer

July 27, 2007

In Brief: Congressional Action Imminent On Cancer Ac Renewal, Hew Money Bills; Veto Threatened

September 8, 1978